Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects With HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors

NCT06714617 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT06714617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06714617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects With HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 10, 2025
Completion date
January 30, 2026
Enrollment
3 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iii, endometrial neoplasms, fallopian tube cancer, gastric cancer, gastroesophageal-junction cancer, her2 gene mutation, her2-positive, her2-positive metastatic breast cancer, non small cell lung cancer, ovarian cancer, peritoneal cancer, solid tumor, adult, unresectable breast carcinoma, urothelial carcinoma bladder